CRISPR Therapeutics AG (CRSP)
50.67
-0.09
(-0.18%)
USD |
NASDAQ |
Nov 04, 16:00
50.50
-0.17
(-0.34%)
After-Hours: 20:00
CRISPR Therapeutics Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 200.00M |
| September 30, 2023 | |
| June 30, 2023 | 70.00M |
| March 31, 2023 | 100.00M |
| December 31, 2022 | 0.006M |
| September 30, 2022 | 0.094M |
| June 30, 2022 | 0.158M |
| March 31, 2022 | 0.178M |
| December 31, 2021 | 12.35M |
| September 30, 2021 | 0.329M |
| June 30, 2021 | 900.20M |
| March 31, 2021 | 0.202M |
| December 31, 2020 | 0.194M |
| September 30, 2020 | 0.148M |
| June 30, 2020 | 0.044M |
| March 31, 2020 | 0.157M |
| December 31, 2019 | 77.02M |
| Date | Value |
|---|---|
| September 30, 2019 | 211.93M |
| June 30, 2019 | 0.318M |
| March 31, 2019 | 0.328M |
| December 31, 2018 | 0.115M |
| September 30, 2018 | 0.563M |
| June 30, 2018 | 1.088M |
| March 31, 2018 | 1.358M |
| December 31, 2017 | 32.32M |
| September 30, 2017 | 2.387M |
| June 30, 2017 | 3.582M |
| March 31, 2017 | 2.703M |
| December 31, 2016 | 2.344M |
| September 30, 2016 | 1.549M |
| June 30, 2016 | 0.795M |
| March 31, 2016 | 0.476M |
| December 31, 2015 | 0.247M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.006M
Minimum
Dec 2022
900.20M
Maximum
Jun 2021
85.07M
Average
0.198M
Median
Revenue (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 2.646B |
| AC Immune SA | 0.7596M |
| Addex Therapeutics Ltd | 0.1275M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.7875M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -126.41M |
| Total Expenses (Quarterly) | 151.26M |
| EPS Diluted (Quarterly) | -1.49 |
| Enterprise Value | 3.839B |
| Earnings Yield | -6.32% |
| Normalized Earnings Yield | -3.809 |